Inituzumab is included in the CACA-CBCS guidelines for the first-line treatment recommendation for advanced HER2-positive breast cancer

Shanghai, November 4, 2021/PRNewswire/ - Recently, the "Chinese Anti-Cancer Association Guidelines and Specifications for Breast Cancer Diagnosis and Treatment (2021 Edition)" (hereinafter referred to as the CACA-CBCS "Guide") was officially released

According to statistics from the International Agency for Research on Cancer (IARC) of the World Health Organization, breast cancer surpassed lung cancer for the first time in 2020, becoming the world's most cancerous cancer

Inituzumab is China's first innovative anti-HER2 monoclonal antibody with Fc segment modification, optimized production process, and stronger ADCC effect

The results of the HOPES study showed that initumumab plus chemotherapy for HER2-positive metastatic breast cancer patients who had previously received one or more chemotherapy regimens, compared with chemotherapy alone, can prolong the median progression-free survival of the primary endpoint (mPFS, 39.

Initumab was approved for marketing by NMPA in June 2020 and entered the national medical insurance in the same year

Professor Zhang Jian from the Cancer Hospital of Fudan University said: “We look forward to the continued expansion of the indications for Inituzumab.

Source: Sansheng Guojian